The different mechanisms leading to ER stress induced by bortezomib and SphK2 inhibition provided the rationale for concomitantly targeting both pathways in myeloma demonstrating a synergistic anti-MM effect in vitro and in vivo. This evidence concerns the gene SPHK2 and Miyoshi myopathy.